Alaunos Therapeutics, Inc.
Business
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing orally administered small-molecule therapeutics for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) using a non-hormonal, non-incretin mechanism. The lead candidate ALN1003 has demonstrated dose-dependent body weight loss, liver-weight reduction, and improved metabolic biomarkers in preclinical mouse models. The company is advancing formulation optimization, chemistry-manufacturing-controls activities, and intellectual-property expansion while planning IND-enabling studies. The company previously developed TCR-engineered T-cell therapies for solid tumors but discontinued clinical development in August 2023.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 5,000 | 10,000 | 5,000 | 3 | 400,000 | |
| Research and development | 1 | 362,000 | 16 | 25 | 50 | |
| General and administrative | 3 | 4 | 12 | 13 | 28 | |
| Total operating expenses | 4 | 5 | 34 | 38 | 78 | |
| Loss from operations | −4 | −5 | −34 | −35 | −78 | |
| Change in fair value of warrant liability | −31,000 | 0 | — | — | — | |
| Other income , net | 80,000 | 133,000 | 1 | 529,000 | −13,000 | |
| Other income (expense), net | 49,000 | 133,000 | −873,000 | −3 | −1 | |
| Net loss | −4 | −5 | −5 | −38 | −79 | |
| Earnings per share, Basic | −2.2 | −2.92 | −21.97 | −2.61 | −0.37 | |
| Earnings per share, Diluted | −2.2 | −2.92 | −21.97 | −2.61 | −0.37 | |
| Weighted average common shares outstanding, basic | 2 | 2 | 2 | 14 | 214 | |
| Weighted average common shares outstanding, diluted | 2 | 2 | 2 | 14 | 214 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 1 | 6 | 39 | 76 | |
| Receivables | 3,000 | 5,000 | 1,000 | 4,000 | 1 | |
| Prepaid expenses and other current assets, current | 600,000 | 2 | 2 | 799,000 | 2 | |
| Total current assets | 2 | 3 | 8 | 54 | 79 | |
| Property and equipment, net | 91,000 | 0 | 2,000 | 8 | 11 | |
| Prepaid expenses and other assets, non current | 887,000 | 0 | — | — | — | |
| Total assets | 3 | 3 | 8 | 65 | 95 | |
| Accounts payable | 613,000 | 516,000 | 616,000 | 1 | 1 | |
| Accrued expenses | 200,000 | 176,000 | 1 | 5 | 6 | |
| Total current liabilities | 813,000 | 692,000 | 2 | 24 | 16 | |
| Total liabilities | 813,000 | 692,000 | 2 | 26 | 37 | |
| Commitments and contingencies (Note 5) | — | — | — | — | — | |
| Common stock $0.001 par value; 50,000,000 shares authorized, 2,349,480 and 1,601,252 shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively | 2,000 | 2,000 | 2,000 | 16,000 | 216,000 | |
| Additional paid-in capital | 927 | 923 | 922 | 919 | 901 | |
| Accumulated deficit | −925 | −920 | −916 | −881 | −843 | |
| Total stockholders' equity | 2 | 2 | 6 | 39 | 58 | |
| Total liabilities and stockholders' equity | 3 | 3 | 8 | 65 | 95 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 7,000 | 2,000 | 2 | 3 | 3 | |
| Common stock issued for services rendered | 382,000 | 0 | — | — | — | |
| Stock-based compensation | 414,000 | 435,000 | 3 | 4 | 11 | |
| Receivables | 2,000 | −4,000 | 3,000 | 1 | 4 | |
| Prepaid expenses and other current assets | 350,000 | 539,000 | −1 | 867,000 | 9 | |
| Accounts payable | 97,000 | −100,000 | −773,000 | −25,000 | 274,000 | |
| Accrued expenses | 24,000 | −1 | −4 | −668,000 | −11 | |
| Net cash flows from operating activities | −3 | −5 | −30 | −29 | −61 | |
| Purchases of property and equipment | −98,000 | 0 | −197,000 | −216,000 | −3 | |
| Net cash flows from investing activities | −98,000 | 0 | 1 | −193,000 | −3 | |
| Proceeds from the issuance of common stock and pre funded warrants, net of offering costs | 2 | 0 | — | — | — | |
| Proceeds from sale of Series A-1 preferred stock | 500,000 | 0 | — | — | — | |
| Proceeds from sale of Series A-2 preferred stock | 850,000 | 0 | — | — | — | |
| Net cash flows from financing activities | 3 | 0 | −18 | 6 | 26 | |
| Net increase (decrease) in cash, cash equivalents | 294,000 | −5 | −47 | −23 | −39 | |
| Cash paid for interest | 0 | 0 | 2 | 2 | 630,000 | |
| Recognition of warrant liability in connection with the equity line of credit agreement | 178,000 | 0 | — | — | — | |
| Amounts included in accrued expenses and accounts payable related to property and equipment | 67,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Alaunos Therapeutics, Inc.'s CIK number?
Alaunos Therapeutics, Inc.'s SEC CIK number is 0001107421 (1107421). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Alaunos Therapeutics, Inc.'s SEC filings?
All of Alaunos Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Alaunos Therapeutics, Inc. last report earnings?
Alaunos Therapeutics, Inc. (TCRT) most recently filed an earnings 8-K with the SEC on Oct 10, 2024, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000950170-24-113960). This is Alaunos Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Alaunos Therapeutics, Inc.'s most recent earnings 8-K?
Alaunos Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Oct 10, 2024 under accession 0000950170-24-113960. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Alaunos Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →